Prediction of intestinal first-pass drug metabolism
- PMID: 17979655
- DOI: 10.2174/138920007782109733
Prediction of intestinal first-pass drug metabolism
Abstract
Despite a lower content of many drug metabolising enzymes in the intestinal epithelium compared to the liver (e.g. intestinal CYP3A abundance in the intestine is 1% that of the liver), intestinal metabolic extraction may be similar to or exceed hepatic extraction. Modelling of events on first-pass through the intestine requires attention to the complex interplay between passive permeability, active transport, binding, relevant blood flows and the intrinsic activity and capacity of enzyme systems. We have compared the predictive accuracy of the "well-stirred" gut model with that of the "Q(Gut)" model. The former overpredicts the fraction escaping first-pass gut metabolism; the latter improves the predictions by accounting for interplay between permeability and metabolism.
Similar articles
-
Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.Curr Drug Metab. 2010 Nov;11(9):716-29. doi: 10.2174/138920010794328913. Curr Drug Metab. 2010. PMID: 21189140
-
Prediction of human pharmacokinetics--gut-wall metabolism.J Pharm Pharmacol. 2007 Oct;59(10):1335-43. doi: 10.1211/jpp.59.10.0002. J Pharm Pharmacol. 2007. PMID: 17910807 Review.
-
Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.Drug Metab Dispos. 2010 Jul;38(7):1147-58. doi: 10.1124/dmd.110.032649. Epub 2010 Apr 5. Drug Metab Dispos. 2010. PMID: 20368326
-
A pharmacokinetic model to differentiate preabsorptive, gut epithelial, and hepatic first-pass metabolism.J Pharmacokinet Biopharm. 1979 Aug;7(4):407-15. doi: 10.1007/BF01062538. J Pharmacokinet Biopharm. 1979. PMID: 512846
-
Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.Curr Drug Metab. 2007 Oct;8(7):685-93. doi: 10.2174/138920007782109805. Curr Drug Metab. 2007. PMID: 17979656 Review.
Cited by
-
ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.Clin Pharmacol Ther. 2013 Jul;94(1):64-79. doi: 10.1038/clpt.2013.45. Epub 2013 Feb 25. Clin Pharmacol Ther. 2013. PMID: 23588311 Free PMC article. Review.
-
Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers.Clin Pharmacokinet. 2014 Oct;53(10):931-41. doi: 10.1007/s40262-014-0166-x. Clin Pharmacokinet. 2014. PMID: 25141974 Free PMC article.
-
Comment on: "A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood".Clin Pharmacokinet. 2016 Jan;55(1):133-7. doi: 10.1007/s40262-015-0348-1. Clin Pharmacokinet. 2016. PMID: 26649873 No abstract available.
-
Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective.Clin Pharmacol Ther. 2025 Feb;117(2):403-420. doi: 10.1002/cpt.3477. Epub 2024 Oct 18. Clin Pharmacol Ther. 2025. PMID: 39422118 Free PMC article. Review.
-
Clinical Exploration and Physiologically Based Modelling of the Impact of Hepatic Impairment on Entrectinib Pharmacokinetics.Clin Pharmacokinet. 2025 Mar;64(3):437-451. doi: 10.1007/s40262-024-01468-y. Epub 2025 Feb 11. Clin Pharmacokinet. 2025. PMID: 39934586 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical